292306
Differential characteristics of unintentional poisoning deaths by main drug classes
Methods: All UP deaths were obtained from Iowa Death Certificates (2009-2011). Main drug classes focused on included illicit drugs, other medications, and alcohol. Bivariate analyses of age, gender, and population size by drug class were performed. Rates of each drug class were calculated for covariates. Logistic regression was used to identify covariates associated with UP deaths among the three drug classes.
Results/Outcomes: There were 462 UP deaths in Iowa. Rates were higher in males across drug class, ages 25-44 for illicit drugs and other medications, and among urban populations for illicit drugs and in rural populations for other medications. Adjusted odds for alcohol-related poisoning deaths were 2.2 times more likely for males and half as likely to occur among those aged 25-44 than other medications. And those living in urban areas were 2.3 times more likely to die from illicit drug poisonings than other medications.
Conclusion: Males and those in urban populations were at increased risk of UP deaths and further investigation is warranted to determine the reason and means of prevention and control of poisoning deaths in this group.
Implementation of health education strategies, interventions and programs
Occupational health and safety
Program planning
Public health or related education
Public health or related research
Learning Objectives:
Explain the importance of examining unintentional poisoning deaths in Iowa.
Demonstrate the magnitude of unintentional poisoning deaths overall and by main drug classes.
Describe the variation of unintentional poisoning deaths across age, gender, and population size by drug class.
Qualified on the content I am responsible for because: I have been working in the area of injury prevention and control with focus on many causes of injury including poisonings for the past 14 years.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.